Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic regimens for metastatic disease. Olaparib was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumeta, Toko, Matsunuma, Ryoichi, Yamaguchi, Kei, Hayami, Ryosuke, Tsuneizumi, Michiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873165/
https://www.ncbi.nlm.nih.gov/pubmed/31762754
http://dx.doi.org/10.1159/000503858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873165/
https://www.ncbi.nlm.nih.gov/pubmed/31762754
http://dx.doi.org/10.1159/000503858

Ejemplares similares